Under the agreement, GSK will pay
Bellus shares closed at
Bellus is developing a treatment for refractory chronic cough which is defined as a persistent cough for more than eight weeks that does not respond to treatment for an underlying condition or is otherwise unexplained.
The acquisition requires approval by a two-thirds majority vote by Bellus shareholders.
The deal is also subject to customary conditions, including court and regulatory approvals.
This report by The Canadian Press was first published
Companies in this story: (TSX:BLU)
© 2023 The Canadian Press. All rights reserved., source